Danaparoid for heparin-induced thrombocytopenia: An analysis of treatment failures

European Journal of Haematology

Volumn 71, Issue 2, 2003, Pages 109-113

  Kodityal, Sandeep ^a   Manhas, Amit H ^a   Udden, Mark ^a,b   Rice, Lawrence ^a,c,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d Mail Sta 902   (United States)

Author keywords

Danaparoid; Heparin; Heparin induced thrombocytopenia; Thrombocytopenia

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; HEPARIN; LEPIRUDIN; TIROFIBAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; FEMALE; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEPARINIZATION; HUMAN; INTESTINE NECROSIS; LEG THROMBOSIS; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; CHONDROITIN SULFATES; CROSS REACTIONS; DERMATAN SULFATE; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG COMBINATIONS; FEMALE; HEPARIN; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

EID: 0041627519     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00105.x     Document Type: Article

References (19)

1. WARKENTIN TE, KELTON JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
2. WALLIS DE, WORKMAN DL, LEWIS BE, STEEN L, PIFARRE R, MORAN JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
3. RICE L, NGUYEN PH, VANN AR. Preventing complications in heparin-induced thrombocytopenia. Postgrad Med 2002;112:85-89.
4. WARKENTIN TE, ELAVATHIL LJ, HAYWARD CPM, JOHNSTON MA, RUSSETT JI, KELTON JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812.
5. SRINIVASAN AF, RICE L, BARTHOLOMEW JR, RANGASWAMY C, LA PERNA L, THOMPSON JE, MURPHY S, BAKER KR. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Int Med 2003 (in press).
6. GREINACHER A, WARKENTIN TE. Treatment of heparin-induced thrombocytopenia: an overview. In WARKENTIN TE, GREINACHER A, Eds. Heparin-induced Thrombocytopenia, 2nd edn. New York: Marcel Dekker, 2001:291-322.
7. MAGNANI HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997;8:74-81.
8. CHONG BH, MAGNANI HN. Danaparoid for the treatment of heparin-induced thrombocytopenia. In WARKENTIN TE, GREINACHER A, Eds. Heparin-induced Thrombocytopenia, 2nd edn. New York: Marcel Dekker, 2001:323-347.
9. WARKENTIN TE. Danaparoid (orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity of danaparoid for HIT-IgG. Blood (suppl.) 1996:626a.
10. RICE L, ATTISHA WK, DREXLER A, FRANCIS JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002;136:210-215.
11. CHONG BH, GALLUS AS, CADE JF et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 2001;86:1170-1175.
12. GREINACHER A, VOLPEL H, JANSSENS U, HACH-WUNDERLE V, KEMKES-MATTHES B, EICHLER P. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;99:73-80.
13. GREINACHER A, EICHLER P, LUBENOW N, KWASNY H, LUZ MI. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of perenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851.
14. LEWIS B, WALLIS DE, BERKOWITZ SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
15. GROSSET ABM, RODGERS GM. Acquired coagulation disorders. In LEE GR, FOERSTER J, LUKENS J, PARASKEVAS F, GREER JP, RODGERS GM, Eds. Wintrobe's Clinical Hematology, 10th edn. Baltimore: Williams & Wilkins, 1999:1733-1780.
16. FARNER B, EICHLER P, KROLL H, GREINACHER A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001;85:950-957.
17. WARKENTIN TE. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost 2001;85:947-949.
18. KENG TB, CHONG BH. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 2001;114:394-396.
19. TARDY B, TARDY-PONCET B, VIALLON A et al. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses. Thromb Haemost 1998;80:530.